Literature DB >> 26045746

Associations of deregulation of mir-365 and its target mRNA TTF-1 and survival in patients with NSCLC.

Ruifang Sun1, Zhigang Liu2, Gang Ma3, Weidong Lv2, Xinliang Zhao4, Guangyan Lei2, Changfu Xu1.   

Abstract

microRNA (mir)-365 exerts tumor suppressor function by targeting thyroid transcription factor-1 (TTF-1) in lung cancer cells. The purpose of the present study was to assess mir-365 and its target mRNA TTF-1 in lung cancer and their correlations with patients' survival. Quantitative real-time PCR was used to examine the expression levels of mir-365 and TTF-1 in tumor tissue and its adjacent noncancerous tissue of 126 patients with non-small cell lung cancer (NSCLC). Our results showed that mir-365 was significantly decreased in tumor tissue than that in normal tissue (P=0.006), however, TTF-1 was significantly increased in tumor tissue than in normal tissue (P<0.001). Besides, significant correlations between decreased mir-365 and advanced tumor-node-metastasis (TNM) stage (P=0.001) and regional lymph node involvement (P=0.037) was observed. The similar result was also found between increased TTF-1 and TNM stage (P=0.003). Furthermore, mir-365 downregulation or TTF-1 upregulation were associated with poor outcome of patients than mir-365 upregulation or TTF-1 downregulation (for mir-365: P<0.001; for TTF-1: P=0.002). Of note, combination of decreased mir-365 and increased TTF-1 had worst overall survival (P<0.001). In conclusion, aberrant expression of mir-365/TTF-1 may be involved in the tumor development in patients with NSCLC. Moreover, mir-365 and TTF-1 could jointly predict the prognosis of patients and their combination may serve as a biomarker to predict risk of poor survival in NSCLC patients. Mir-365/TTF-1 might serve as a potential therapeutic target for clinical treatment of NSCLC.

Entities:  

Keywords:  NKX2-1; microRNA-365; non-small cell lung cancer; outcome; prognostic

Mesh:

Substances:

Year:  2015        PMID: 26045746      PMCID: PMC4440055     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

Review 1.  The diverse functions of microRNAs in animal development and disease.

Authors:  Wigard P Kloosterman; Ronald H A Plasterk
Journal:  Dev Cell       Date:  2006-10       Impact factor: 12.270

Review 2.  Clinical applications for microRNAs in cancer.

Authors:  S P Nana-Sinkam; C M Croce
Journal:  Clin Pharmacol Ther       Date:  2012-12-05       Impact factor: 6.875

3.  MicroRNA-365 regulates NKX2-1, a key mediator of lung cancer.

Authors:  Sung-Min Kang; Heon-Jin Lee; Je-Yoel Cho
Journal:  Cancer Lett       Date:  2013-03-16       Impact factor: 8.679

4.  MicroRNA-33a mediates the regulation of high mobility group AT-hook 2 gene (HMGA2) by thyroid transcription factor 1 (TTF-1/NKX2-1).

Authors:  Shawn J Rice; Shao-Chiang Lai; Lauren W Wood; Kaitlin R Helsley; E Aaron Runkle; Monte M Winslow; David Mu
Journal:  J Biol Chem       Date:  2013-04-26       Impact factor: 5.157

5.  Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.

Authors:  T Berghmans; M Paesmans; C Mascaux; B Martin; A-P Meert; A Haller; J-J Lafitte; J-P Sculier
Journal:  Ann Oncol       Date:  2006-09-15       Impact factor: 32.976

6.  Increased ZO-1 expression predicts valuable prognosis in non-small cell lung cancer.

Authors:  Songshi Ni; Liqin Xu; Jianfei Huang; Jian Feng; Huijun Zhu; Gui Wang; Xudong Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-11-15

7.  MicroRNA signature predicts survival and relapse in lung cancer.

Authors:  Sung-Liang Yu; Hsuan-Yu Chen; Gee-Chen Chang; Chih-Yi Chen; Huei-Wen Chen; Sher Singh; Chiou-Ling Cheng; Chong-Jen Yu; Yung-Chie Lee; Han-Shiang Chen; Te-Jen Su; Ching-Cheng Chiang; Han-Ni Li; Qi-Sheng Hong; Hsin-Yuan Su; Chun-Chieh Chen; Wan-Jiun Chen; Chun-Chi Liu; Wing-Kai Chan; Wei J Chen; Ker-Chau Li; Jeremy J W Chen; Pan-Chyr Yang
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

Review 8.  The complexity of thyroid transcription factor 1 with both pro- and anti-oncogenic activities.

Authors:  David Mu
Journal:  J Biol Chem       Date:  2013-07-01       Impact factor: 5.157

Review 9.  NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression.

Authors:  Tomoya Yamaguchi; Yasuyuki Hosono; Kiyoshi Yanagisawa; Takashi Takahashi
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

10.  Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency.

Authors:  Shui-Long Guo; Hui Ye; Yan Teng; You-Liang Wang; Guan Yang; Xiu-Bin Li; Chong Zhang; Xue Yang; Zhong-Zhou Yang; Xiao Yang
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  6 in total

1.  MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.

Authors:  Yanli Wang; Chunling Xu; Yun Wang; Xiaomeng Zhang
Journal:  Am J Cancer Res       Date:  2017-05-01       Impact factor: 6.166

2.  NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer.

Authors:  Jorge Moisés; Alfons Navarro; Sandra Santasusagna; Nuria Viñolas; Laureano Molins; José Ramirez; Jeisson Osorio; Adela Saco; Joan Josep Castellano; Carmen Muñoz; Sara Morales; Mariano Monzó; Ramón María Marrades
Journal:  BMC Pulm Med       Date:  2017-12-13       Impact factor: 3.317

Review 3.  Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Authors:  Hildegard Kehrer-Sawatzki; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2017-02-17       Impact factor: 4.132

4.  Genome-wide association study of prevalent and persistent cervical high-risk human papillomavirus (HPV) infection.

Authors:  Sally N Adebamowo; Adebowale A Adeyemo; Charles N Rotimi; Olayinka Olaniyan; Richard Offiong; Clement A Adebamowo
Journal:  BMC Med Genet       Date:  2020-11-23       Impact factor: 2.103

5.  Establishment and validation of a 7-microRNA prognostic signature for non-small cell lung cancer.

Authors:  Nan Wang; Huihui Guo; Zhaohuo Dong; Qiuqiang Chen; Xilin Zhang; Weiyun Shen; Ying Bao; Xiang Wang
Journal:  Cancer Manag Res       Date:  2018-09-12       Impact factor: 3.989

Review 6.  MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.

Authors:  Rahaba Marima; Flavia Zita Francies; Rodney Hull; Thulo Molefi; Meryl Oyomno; Richard Khanyile; Sikhumbuzo Mbatha; Mzubanzi Mabongo; David Owen Bates; Zodwa Dlamini
Journal:  Biomedicines       Date:  2021-12-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.